导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.55% | 1795/4773 |
| 近一周 | -2.24% | 2649/5458 |
| 近一月 | -4.90% | 3141/5421 |
| 近一季 | -5.66% | 2904/5205 |
| 近半年 | -6.79% | 3205/4920 |
| 近一年 | 6.53% | 1569/4361 |
| 近两年 | 67.53% | 1040/2954 |
| 近三年 | 34.21% | 903/2253 |
| 成立以来 | 63.02% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.24% 1000/4961 |
17.77% 1452/5312 |
- - |
- - |
| 2025 | 28.91% 1438/4813 |
2.07% 1475/3635 |
1.80% 2130/4076 |
23.15% 1572/4524 |
0.74% 1804/4813 |
| 2024 | 6.55% 1748/3463 |
-2.67% 1404/2808 |
-5.01% 1620/3014 |
15.09% 1815/3129 |
0.14% 1261/3463 |
| 2023 | -6.36% 835/2656 |
7.19% 592/2280 |
-4.11% 1055/2385 |
-4.56% 1161/2515 |
-4.54% 1083/2655 |
| 2022 | -17.79% 630/2207 |
-13.31% 730/1919 |
3.10% 1215/2016 |
-10.28% 375/2113 |
2.51% 912/2208 |
| 2021 | 14.53% 329/1822 |
-1.46% 495/1255 |
8.44% 623/1330 |
4.14% 379/1466 |
2.93% 493/1822 |
| 2020 | - - |
- - |
- - |
11.20% 470/1164 |
2.93% 954/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 中银证券中证500ETF联接A VS. 长安沪深300非周期A(740101) |